0:00
0:28 Introducing Dr. Mike Putman
2:07 Explaining the PEXIVAS Trial
3:12 What is a Randomized Controlled Trial (RCT)?
6:16 What is plasma exchange?
9:14 A closer look at the demographics of participants in the PEXIVAS trial.
10:25 Primary outcomes from this study.
13:33 What did the primary outcomes show about infections?
14:24 Limitations of the PEXIVAS study.
17:39 Plasma exchange and insurance coverage.
19:04 Explaining this sentence: “The primary outcome is the time to the composite of all-cause
mortality and end-stage renal disease.”
21:15 Explaining this sentence: “Additional potential beneficial effects of PLEX in AAV include
removal of other mediators of inflammation and coagulation and effects on
immunoregulation.
22:30 Is the PEXIVAS study still recruiting?
24:03 How the PEXIVAS study is a model for international research collaboration.
Overview of the PEXIVAS Study
Recorded May 2024